From Siemens Medical Systems;
while older navigator techniques take up to 40 minutes to create, the high performance of the MAGNETOM Sonata system enables 'complete examinations in less than 15 minutes'. It creates a new standard of diagnostic confidence and moves Cardiac MR from the research setting into routine clinical practice.

From Siemens Medical Systems;
The Magnetom Trio™, a 3T whole body MRI system with Tim (total imaging matrix technology), targets clinical applications such as abdominal, cardiac, spine, whole body and orthopedics. TIM enables flexible coil combinations for high resolution imaging of large anatomical areas without the need to change coils.

From Siemens Medical Systems;
70 cm + 125 cm + 1.5T and Tim - a combination never seen before in MRI ... MAGNETOM Espreeâ„¢s unique open bore design can accommodate more types of patients than other 1.5T systems on the market today, in particular the growing population of obese patients. The power of 1.5T combined with Tim technology boosts signal to noise, which is necessary to adequately image obese patients.

(B) Also called magnetic flux density with the SI unit tesla (T) usually denoted by the symbol B. The magnetic induction is the net magnetic effect from an externally applied magnetic field and the resulting magnetization.
The symbol H was used for the magnetic field (measured in amperes per meter (A/m)). However, this distinction is often ignored, and both quantities are often referred to as the magnetic field.
B is proportional to H (B = μH).
(μ is the magnetic permeability (in henries per meter) of the medium)

Short name: NC100150, PEG-feron, generic name: Feruglose, preliminary trade name: Clariscanâ„¢
NC100150 injection is the code name for an USPIO (ultrasmall superparamagnetic iron oxide) MRI contrast agent under development. Microvessel permeability depends on functional and morphologic characteristics of cancer vessels and on physicochemical properties of the injected contrast medium molecule.
USPIO particles have a favorable pharmacological and tolerance profile and are being tested clinically of the potential for the quantitative characterization of tumor microvasculature and specifically for measures of the microvessel permeability. Iron-based products take advantage of their large molecular size, which prevents diffusion into body tissues. These agents are disposed of by the liver and spleen as particulate matter.
NC100150 Injection (Nycomed Amersham, Amersham Health ) consists of USPIO particles that are composed of single crystals (4- to 7-nm diameter) and stabilized with a carbohydrate polyethylene glycol (PEG) coat. The iron oxide particles have to be suspended in an isotonic glucose solution. The final diameter of an USPIO particle is approximately 20 nm. Blood pool half-life is more than two hours in humans; the particles are taken up by the mononuclear phagocyte system and distributed mainly to the liver and spleen.
NC100150 would compete with the contrast agents Ferumoxytol from AMAG Pharmaceuticals, Inc. and Vasovistâ„¢ from EPIX Pharmaceuticals, Inc., but at this time the development of NC100150 Injection/Clariscan™ is discontinued.